Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (March 2022)
12 slides from Rhythm Biosciences's investor presentation, Mar 2, 2022
Slide 1: Investor Webinar
Investor Webinar 2 March 2022 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction Rhythm’s initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. 3
Slide 4: Agenda
Agenda Overview of commercialisation progress for ColoSTAT® - a simple, low-cost, blood test for global mass market detection of colorectal cancer; Rhythm’s platform technology expansion strategy into other cancer targets; Future catalysts and news flow for the current calendar year; and A q
Slide 5: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY $7,000,000 $2.50 Share Price (at 1 March 2022) $1.18 $6,000,000 $2.00 $5,000,000 Shares on Issue 214.1 M $4,000,000 $1.50 Unlisted Options 16.8 M $3,000,000 $1.00 Market Capitalisation $251.6 M $2,000,000 $0.50 $1,000,000 Cash in bank
Slide 6: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market US$38 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States 63% 94 million $12Bn
Slide 7: ColoSTAT Performance
ColoSTAT® Performance “83% of unscreened participants prefer a blood test over a faecal test”1 ColoSTAT Sensitivity Performance Comparison • Highly accurate 85% ColoSTAT is 33% more accurate at detecting colorectal cancer than the current market standard Faecal Immunochemical Test (FIT).2 84% 80% 75
Slide 8: Clinical Trial (Study 7) – Performance In A Clinical Setting
Clinical Trial (Study 7) – Performance In A Clinical Setting PRIMARY ENDPOINT: Performance of ColoSTAT® for detection of CRC relative to colonoscopy (Sensitivity and Specificity). Key Steps (not exhaustive list): Complete patient recruitment. Done. Statistical analysis of results. Underway.
Slide 9: Platform Technology Expansion
Platform Technology Expansion • The expansion program is expected to be significantly shortened, leveraging the Company’s lead biomarker which exhibits pan-cancerous properties; • A platform expansion program identified a number of additional cancer target markets that will form part of a new Resear
Slide 10: Appointment of General Counsel & Co Sec
Appointment of General Counsel & Co Sec Ms Andrea Steele has been appointed as General Counsel and Company Secretary; Ms Steele has a Bachelor of Laws (LLB), a Master of Laws (LLM), a Master of Legal Practice and a Bachelor of Commerce (Accounting / Finance); Career spanning over 23 years and
Slide 11: CY'22 Catalysts
CY’22 Catalysts Clinical Trial (Study 7) results and clinical study report completion; Technical file complete for ARTG listing for TGA submission and approval; Identify and progress partnering / commercialisation deals (Domestic and International); International country submissions / regist
Slide 12: Glenn Gilbert
Glenn Gilbert CEO and Managing Director, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com 12
Rhythm Biosciences — Investor Presentation (March 2022) on 6ix